Compared to healthy controls, MS patients show significantly downregulated expression of TET2 in peripheral blood mononuclear cells (PBMCs), correlating with abnormal methylation patterns in the promoter regions of TET2 and DNMT1 (134). This evidence concerns the gene TET2 and myeloid sarcoma.